Human ADSC xenograft through IL-6 secretion activates M2 macrophages responsible for the repair of damaged muscle tissue.
Blood vessels
IL-6
M2 macrophages
Repairing damaged muscle
Xenograft
hADSCs
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
13 03 2019
13 03 2019
Historique:
received:
24
07
2018
accepted:
25
02
2019
revised:
25
01
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
23
4
2020
Statut:
epublish
Résumé
Adipose-derived mesenchymal stromal cells (ADSCs) are multipotent stromal cells. The cells secrete a number of cytokines and growth factors and show immunoregulatory and proangiogenic properties. Their properties may be used to repair damaged tissues. The aim of our work is to explain the muscle damage repair mechanism with the utilization of the human adipose-derived mesenchymal stromal cells (hADSCs). For the hADSCs isolation, we used the subcutaneous adipose tissue collected during the surgery. The murine hind limb ischemia was used as a model. The unilateral femoral artery ligation was performed on 10-12-week-old male C57BL/6NCrl and NOD SCID mice. The mice received PBS The retention time of hADSCs in the limb lasted about 14 days. In the mice receiving hADSCs, the improvement in the functionality of the damaged limb occurred faster than in the control mice. More new blood vessels were formed in the limbs of the mice receiving hADSCs than in limbs of the control mice. hADSCs also increased the infiltration of the macrophages with the M2 phenotype (7-AAD The proposed mechanism for the repair of the damaged muscle using hADSCs is based on the activity of IL-6. In our opinion, the cytokine, secreted by the hADSCs, stimulates the M2 macrophages responsible for repairing damaged muscle and forming new blood vessels.
Sections du résumé
BACKGROUND
Adipose-derived mesenchymal stromal cells (ADSCs) are multipotent stromal cells. The cells secrete a number of cytokines and growth factors and show immunoregulatory and proangiogenic properties. Their properties may be used to repair damaged tissues. The aim of our work is to explain the muscle damage repair mechanism with the utilization of the human adipose-derived mesenchymal stromal cells (hADSCs).
METHODS
For the hADSCs isolation, we used the subcutaneous adipose tissue collected during the surgery. The murine hind limb ischemia was used as a model. The unilateral femoral artery ligation was performed on 10-12-week-old male C57BL/6NCrl and NOD SCID mice. The mice received PBS
RESULTS
The retention time of hADSCs in the limb lasted about 14 days. In the mice receiving hADSCs, the improvement in the functionality of the damaged limb occurred faster than in the control mice. More new blood vessels were formed in the limbs of the mice receiving hADSCs than in limbs of the control mice. hADSCs also increased the infiltration of the macrophages with the M2 phenotype (7-AAD
CONCLUSIONS
The proposed mechanism for the repair of the damaged muscle using hADSCs is based on the activity of IL-6. In our opinion, the cytokine, secreted by the hADSCs, stimulates the M2 macrophages responsible for repairing damaged muscle and forming new blood vessels.
Identifiants
pubmed: 30867059
doi: 10.1186/s13287-019-1188-y
pii: 10.1186/s13287-019-1188-y
pmc: PMC6417195
doi:
Substances chimiques
IL6 protein, human
0
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
93Références
World J Stem Cells. 2011 Jan 26;3(1):1-8
pubmed: 21607131
PLoS One. 2016 Jul 14;11(7):e0158745
pubmed: 27415778
Biochim Biophys Acta. 2011 May;1813(5):878-88
pubmed: 21296109
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
Stem Cell Res Ther. 2012 Jul 30;3(4):28
pubmed: 22846185
Cell Stem Cell. 2013 Oct 3;13(4):392-402
pubmed: 24094322
Cardiovasc Res. 2011 Feb 15;89(3):650-60
pubmed: 20833652
Cell Physiol Biochem. 2006;17(5-6):279-90
pubmed: 16791003
Stem Cell Res Ther. 2017 Jun 5;8(1):125
pubmed: 28583178
FEBS Lett. 1989 Jan 2;242(2):237-9
pubmed: 2464504
Am J Physiol Regul Integr Comp Physiol. 2012 Jul 1;303(1):R48-56
pubmed: 22573106
J Thorac Cardiovasc Surg. 2005 Oct;130(4):1114-21
pubmed: 16214528
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
Nat Rev Immunol. 2012 Apr 25;12(5):383-96
pubmed: 22531326
Immunol Cell Biol. 2013 Jan;91(1):27-31
pubmed: 23146943
BMC Neurosci. 2008 Feb 12;9:21
pubmed: 18269732
Biochim Biophys Acta Mol Basis Dis. 2017 Apr;1863(4):857-869
pubmed: 28087471
Blood. 2007 Nov 15;110(10):3499-506
pubmed: 17664353
Ann Thorac Surg. 2002 Jul;74(1):19-24; discussion 24
pubmed: 12118756
Trends Biotechnol. 2006 Apr;24(4):150-4
pubmed: 16488036
Cancer Sci. 2017 Oct;108(10):1939-1946
pubmed: 28756624
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):419-27
pubmed: 19926330
Transfus Med Hemother. 2016 Jul;43(4):268-274
pubmed: 27721702
Oncotarget. 2017 Jun 6;8(23):38008-38021
pubmed: 28402942
Radiology. 2017 Aug;284(2):495-507
pubmed: 28128708
Stem Cell Res Ther. 2017 Dec 06;8(1):277
pubmed: 29212557
Nat Immunol. 2014 May;15(5):423-30
pubmed: 24681566
Stem Cells Int. 2018 Aug 19;2018:8031718
pubmed: 30210552
World J Stem Cells. 2017 Aug 26;9(8):107-117
pubmed: 28928907
Nat Immunol. 2014 Nov;15(11):1009-16
pubmed: 25329189
Stem Cell Res Ther. 2018 Apr 3;9(1):88
pubmed: 29615126
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7099-103
pubmed: 3262872
Brain Res. 2008 Nov 6;1239:49-55
pubmed: 18804456
Exp Hematol. 2002 Jan;30(1):42-8
pubmed: 11823036
J Thorac Cardiovasc Surg. 2004 May;127(5):1293-300
pubmed: 15115985
Transplantation. 2003 Feb 15;75(3):389-97
pubmed: 12589164
Am J Transplant. 2012 Sep;12(9):2373-83
pubmed: 22642544
Future Cardiol. 2016 Sep;12(5):585-99
pubmed: 27420190
Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1428-38
pubmed: 20852053
Front Physiol. 2014 Jan 09;4:402
pubmed: 24409152